Lifeline BioTechnologies Signs Letter of Intent to Acquire GlobalOdds Holdings, a Premium Technology Provider in Online Gaming
Summary
Aventura, FL, May 17, 2025 --( PR.com )-- Lifeline BioTechnologies, Inc., a publicly traded company (OTC: LLBO), today announced it has signed a Letter of Intent (LOI) to acquire GlobalOdds Holdings Pty. The company has developed proprietary technology and infrastructure spanning multiple gaming verticals, including sports wagering technologies, casino game integration systems, advanced customer relationship management tools, horse racing platforms, artificial intelligence-driven personalization engines, and secure payment processing frameworks. The company’s technological innovation focuses on enhancing player engagement, optimizing retention metrics, and maximizing operator revenue through data-driven personalization and robust back-office systems.This acquisition is LLBO’s initial entry into software development for the global gaming sector and supports its transformation into a diversified online software development platform.“The LOI with GlobalOdds marks a major milestone in our strategic roadmap,” said Greg Klok, CEO of LLBO. “GlobalOdds has built a world-class technology stack and has strong market traction in key regions. This acquisition positions LLBO to capitalize on the growth in the global online wagering industry, projected by Horizon Research[1] to reach over $153 billion by 2030.”Highlights of the Transaction:GlobalOdds powers numerous enterprise-level gaming operations across multiple markets through its industry-leading platform technology, serving a diverse portfolio of B2B clients via SaaS and revenue-sharing partnerships.The acquisition includes proprietary technology, established customer base, and strategic expansion plans into Australia and beyond.The LOI outlines the framework for the proposed acquisition, which remains subject to customary due diligence, negotiation of definitive agreements, regulatory approvals, and other closing conditions.Following the successful completion of this transaction LLBO intends to divest its current biotechnology business.About Lifeline BioTechnologies, Inc. (LLBO)LLBO is a publicly traded company focused on strategic acquisitions in high-growth digital sectors.